Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity

International Journal of Tuberculosis and Lung Disease

Volumn 4, Issue 3, 2000, Pages 256-261

  Ohno, M ^a   Yamaguchi, J ^a   Yamamoto, I ^a   Fukuda, T ^b   Yokota, S ^b   Maekura, R ^b   Ito, M ^b   Yamamoto, Y ^b   Ogura, T ^b   Maeda, K ^c   Komuta, K ^c   Igarashi, T ^c   Azuma, J ^a  

^a OSAKA UNIVERSITY   (Japan)

^b TONEYAMA NATIONAL HOSPITAL   (Japan)

^c NIT West Osaka Hospital   (Japan)

Author keywords

Genotype; Hepatotoxicity; Isoniazid; N acetyltransferase 2 (NAT2); Rifampicin

Indexed keywords

ACYLTRANSFERASE; AMINOTRANSFERASE; ISONIAZID; RIFAMPICIN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; FEMALE; GENOTYPE; HUMAN; INCIDENCE; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; ISONIAZID; JAPAN; LIVER DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 17644441355     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Steele M A, Burk R F, DesPrez R M. Toxic hepatitis with isoniazid and rifampin a meta-analysis. Chest 1991; 99: 465-471.
2. Sarma G R, Immanuel C, Kailasam S, Narayana A S L, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986; 133: 1072-1075.
3. Mitchell J R, Thorgeirsson U P, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin Pharmacol Ther 1975; 18: 70-79.
4. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990; 265: 12757-12760.
5. Parkin D P, Vandenplas S, Botha F J H, et al. Trimodality of isoniazid elimination. Phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155: 1717-1722.
6. Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986; 6: 295-298.
7. Satinder L A L, Singhal S N, Burley D M, Crossley G. Effect of rifampicin and isoniazid on liver function. Br Med J 1972; 1: 148-150.
8. Grönhagen-Riska C, Hellstrom P E, Fröseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118: 461-466.
9. Parthasarathy R, Sarma G R, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986; 67: 99-108.
10. Singh J, Garg P, Thakur V S, Tandon R K. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter? Indian J Physiol Pharmacol 1995; 39: 43-46.
11. Vatsis K P, Weber W W, Bell D A, et al. Nomenclanture for N-acetyltransferases. Pharmacogenetics 1995; 5: 1-17.
12. Neugebauer S, Baba T, Watanabe T, Ishizaki T, Kurokawa K. The N-acetyltransferase (NAT) gene: an early risk marker for diabetic nephrophathy in Japanese type 2 diabetic patients? Diabet Med 1994; 11: 783-788.
13. Mashimo M, Suzuki T, Abe M, Deguchi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 1992; 90: 139-143.
14. Abe M, Deguchi T, Suzuki T. The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem Biophy Res Commun 1993; 191: 811-816.
15. Yokoi T, Sawada M, Kamataki T. Polymorphic drug metabolism: Studies with recombinant Chinese hamster cells and analyses in human populations. Pharmacogenetics 1995; 5: S56-S59.
16. Okumura K, Kita T, Chikazawa S, Komada F, Iwakawa S, Tanigawara Y. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin Pharmacol Ther 1997; 61: 509-517.
17. Girling D J. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle, 1978; 59: 13-32.
18. Mitchell J R, Zimmerman H J, Ishak K G, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976; 84: 181-192.
19. Timbrell J A, Mitchell J R, Snodgrass W R, Nelson S D. Isoniazid hepatotoxicity: The relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 1980; 213: 364-369.
20. Peretti E, Karlaganis G, Lauterburg B H. Acetylation of acetylhydrazine, the toxic metabolite of isoniazid, in humans. Inhibition by concomitant administration of isoniazid. J Pharmacol Exp Ther 1987; 243: 686-689.
21. Lauterburg B H, Smith C V, Todd E L, Mitchell J R. Pharmacokinetcs of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 1985; 235: 566-570.
22. Lauterburg B H, Smith C V, Todd E L, Mitchell J R. Oxidation of hydrazine metabolites formed from isoniazid. Clin Pharmacol Ther 1985; 38: 566-571.
23. Jenner P J, Ellard G A. Isoniazid-related hepatotoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Tubercle 1989; 70: 93-101.
24. Ellard G A, Gammon P T. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 1976; 4: 83-115.
25. Blair I A, Mansilla Tinoco R, Brodie M J, et al. Plasma hydrazine concentrations in man after isoniazid and hydralazine administration. Hum Toxicol 1985; 4: 195-202.
26. Beever I A, Blair I W, Brodie M J. Circulating hydrazine during treatment with isoniazid rifampicin in man. Br J Clin Pharmacol 1982; 13: 599.
27. Singapore Tuberculosis Service/British Medical Research Council. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore. Am Rev Respir Dis 1977; 116: 807-820.
28. Ellard G A, Mitchison D A, Girling D J, Nunn A J, Fox W. The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug. Am Rev Respir Dis 1978; 118: 628-629.
29. Ellard G A, Girling D J, Nunn A J. The hepatic toxicity of isoniazid among the three acetylator phenotypes. Am Rev Respir Dis 1981; 123: 568-570.